• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Neal I. Lindeman, MD


  • Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, Jane-Valbuena J, Friedrich DC, Kryukov G, Carter SL, McKenna A, Sivachenko A, Rosenberg M, Kiezun A, Voet D, Lawrence M, Lichtenstein LT, Gentry JG, Huang FW, Fostel J, Farlow D, Barbie D, Gandhi L, Lander ES, Gray SW, Joffe S, Janne P, Garber J, MacConaill L, Lindeman N, Rollins B, Kantoff P, Fisher SA, Gabriel S, Getz G, Garraway LA.Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.Nat Med. 2014 Jun;20(6):682-8.
  • Cagle PT, Sholl LM, Lindeman NI, Alsabeh R, Divaris DX, Foulis P, Lee G, Neal JW, Nowak JA, Yu PP, .Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung.Arch Pathol Lab Med. 2014 Feb;138(2):171-4.
  • Boyer DF, Lindeman NI, Harris NL, Ferry JA.Peripheral T-cell lymphomas with cytotoxic phenotype in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.Am J Surg Pathol. 2014 Feb;38(2):279-88.
  • Brunner AM, Costa DB, Heist RS, Garcia E, Lindeman NI, Sholl LM, Oxnard GR, Johnson BE, Hammerman PS.Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.J Thorac Oncol. 2013 Nov;8(11):1434-7.
  • Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Arch Pathol Lab Med. 2013 Jun;137(6):828-60.
  • Sadrzadeh H, Kerr DA, Cin PD, Lindeman NI, Hasserjian RP, Fathi AT.A unique PML-RARα rearrangement involving chromosomes 11, 15, and 17 in a patient with acute promyelocytic leukemia.Exp Hematol. 2013 May 6.
  • Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M.Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.J Mol Diagn. 2013 Apr 4.
  • Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M.Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.J Thorac Oncol. 2013 Apr 2.
  • Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, Morra E, Trojani A, Greco A, Arcaini L, Varettoni M, Varettoni M, Brown JR, Tai YT, Anderson KC, Munshi NC, Patterson CJ, Manning RJ, Tripsas CK, Lindeman NI, Treon SP.MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.Blood. 2013 Mar 14;121(11):2051-8.
  • Sholl LM, Weremowicz S, Gray SW, Wong KK, Chirieac LR, Lindeman NI, Hornick JL.Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.J Thorac Oncol. 2013 Mar;8(3):322-8.
  • Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, Jackman DM, Johnson BE, Jänne PA.Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.J Thorac Oncol. 2013 Feb;8(2):179-84.
  • Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Jänne PA, Lindeman NI, Johnson BE.The introduction of systematic genomic testing for patients with non-small-cell lung cancer.J Thorac Oncol. 2012 Dec;7(12):1767-74.
  • Lindeman NI, Melanson SE, McDonnell A, Deangelo DJ, Jarolim P.Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase.Clin. Chem. Lab. Med. 2012 Oct 19;0(0):1-5.
  • Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.Clin Cancer Res. 2012 Aug 15;18(16):4406-14.
  • Morikawa T, Shima K, Kuchiba A, Yamauchi M, Tanaka N, Imamura Y, Liao X, Qian ZR, Brahmandam M, Longtine JA, Lindeman NI, Fuchs CS, Ogino S.No evidence for interference of h&e staining in DNA testing: usefulness of DNA extraction from h&e-stained archival tissue sections.Am J Clin Pathol. 2012 Jul;138(1):122-9.
  • Uljon SN, Richardson PG, Schur PH, Anderson KC, Tanasijevic MJ, Lindeman NI.Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma.Clin Chim Acta. 2011 Mar 18;412(7-8):562-8.
  • Sholl LM, Xiao Y, Joshi V, Yeap BY, Cioffredi LA, Jackman DM, Lee C, Jänne PA, Lindeman NI.EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry.Am J Clin Pathol. 2010 Jun;133(6):922-34.
  • Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, Cohen DW, Johnson BE, Jänne PA, Iafrate AJ, Rodig SJ.A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.Clin Cancer Res. 2010 Mar 1;16(5):1561-71.
  • Irahara N, Nosho K, Baba Y, Shima K, Lindeman NI, Hazra A, Schernhammer ES, Hunter DJ, Fuchs CS, Ogino S.Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells.J Mol Diagn. 2010 Mar;12(2):177-83.
  • Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA.Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.Cancer Cell. 2010 Jan 19;17(1):77-88.
  • Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson LA, Stiedl AC, Tanaka KE, Bass AJ, Barretina J, Weir BA, Beroukhim R, Thomas RK, Minna JD, Chirieac LR, Lindeman NI, Giordano T, Beer DG, Wagner P, Wistuba II, Rubin MA, Meyerson M.Amplification of chromosomal segment 4q12 in non-small cell lung cancer.Cancer Biol Ther. 2009 Nov;8(21):2042-50.
  • Wu D, Dutra B, Lindeman N, Takahashi H, Takeyama K, Harris NL, Pinkus GS, Longtine J, Shipp M, Kutok JL.No evidence for the JAK2 (V617F) or JAK2 exon 12 mutations in primary mediastinal large B-cell lymphoma.Diagn Mol Pathol. 2009 Sep;18(3):144-9.
  • Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR.Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.Clin Cancer Res. 2009 Aug 15;15(16):5216-23.
  • Smouse JH,Cibas ES,Janne PA,Joshi VA,Zou KH,Lindeman NI.EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer.Cancer Cytopathol. 2009 Feb 25;117(1):67-72.
  • Yonesaka K,Zejnullahu K,Lindeman N,Homes AJ,Jackman DM,Zhao F,Rogers AM,Johnson BE,Janne PA.Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.Clin Cancer Res. 2008 Nov 1;14(21):6963-73.
  • Koivunen JP,Mermel C,Zejnullahu K,Murphy C,Lifshits E,Holmes AJ,Choi HG,Kim J,Chiang D,Thomas R,Lee J,Richards WG,Sugarbaker DJ,Ducko C,Lindeman N,Marcoux JP,Engelman JA,Gray NS,Lee C,Meyerson M,Janne PA.EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Clin Cancer Res. 2008 Jul 1;14(13):4275-83.
  • Gleason BC, Brinster NK, Granter SR, Pinkus GS, Lindeman NI, Miller DM.Intravascular cytotoxic T-cell lymphoma: A case report and review of the literature.J Am Acad Dermatol. 2008 Feb;58(2):290-4. Review.
  • Lindeman NI, Freeto SM, Jarolim P.Immunosuppressant monitoring can be performed by UPLC-Tandem Mass Spectrometry in half the time needed for conventional HPLC-Tandem Mass Spectrometry, with comparable analytical performance.Clin Chim Acta. 2008 Feb;388(1-2):207-10.
  • Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M.Characterizing the cancer genome in lung adenocarcinoma.Nature. 2007 Dec 6;450(7171):893-8.
  • Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Janne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK.LKB1 modulates lung cancer differentiation and metastasis.Nature. 2007 Aug 16;448(7155):807-10.
  • Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, Jnne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK.Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.Cancer Cell. 2007 Jul;12(1):81-93.
  • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jnne PA.MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling.Science. 2007 May 18;316(5827):1039-43.
  • Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jnne PA.Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.J Clin Oncol. 2007 Mar 1;25(7):760-6.
  • Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jnne PA, Johnson BE.Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.J Clin Oncol. 2006 Sep 20;24(27):4517-20.
  • Sequist LV, Joshi VA, Jnne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ.Epidermal growth factor receptor mutation testing in the care of lung cancer patients.Clin Cancer Res. 2006 Jul 15;12(14):4403s-8s. Review.
  • Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jnne PA.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Clin Cancer Res. 2006 Jul 1;12(13):3908-14.
  • Thomas RK, Nickerson E, Simons JF, Janne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, Gutmann EJ, Dragnev KH, DeBiasi R, Chen TH, Glatt KA, Greulich H, Desany B, Lubeski CK, Brockman W, Alvarez P, Hutchison SK, Leamon JH, Ronan MT, Turenchalk GS, Egholm M, Sellers WR, Rothberg JM, Meyerson M.Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing.Nat Med. 2006 Jul;12(7):852-855.
  • Jnne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, Lindeman N, Lee JC, Halmos B, Maher EA, Distel RJ, Meyerson M, Johnson BE.A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):751-8.
  • Paez JG, Jnne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M.EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy.Science. 2004 Jun 4;304(5676):1497-500.
  • Lindeman N, Waltregny D, Signoretti S, Loda M.Gene transcript quantitation by real-time RT-PCR in cells selected by immunohistochemistry-laser capture microdissection.Diagn Mol Pathol. 2002 Dec;11(4):187-92.
  • Wu BL, Lindeman N, Lip V, Adams A, Amato RS, Cox G, Irons M, Kenna M, Korf B, Raisen J, Platt O.Effectiveness of sequencing connexin 26 (GJB2) in cases of familial or sporadic childhood deafness referred for molecular diagnostic testing.Genet Med. 2002 Jul-Aug;4(4):279-88.
  • Grossfeld GD, Carroll PR, Lindeman N, Meng M, Groshen S, Feng AC, Hawes D, Cote RJ.Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression.Urology. 2002 Jan;59(1):97-102.